Skip to content
TrialScanner

NCT05753189

Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia Subjects

Phase 3CompletedLENZLead

Registry record

Lead sponsor
LENZ Therapeutics, Inc
Conditions
Presbyopia; Near Vision; Refractive Error; Eye Diseases
Primary completion
Feb 9, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05753189 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.